Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

From symptom control to disease modification: non-malignant hematology highlights from ASH 2025

VJHemOnc is thrilled to bring you a feature article on the rise of disease modifying therapies in non-malignant hematology at…

Read More

FDA grants approval to mitapivat for non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia

On December 23, 2025, the U.S. Food and Drug Administration (FDA) granted approval to mitapivat for the treatment of adult…

Read More

FDA approves ziftomenib for NPM1-mutated R/R AML

On November 13, 2025, the US Food and Drug Administration (FDA) approved the menin inhibitor ziftomenib for adult patients with…

Read More

FDA approves revumenib for patients with R/R AML and a susceptible NPM1 mutation

On October 24, 2025, the U.S. Food and Drug Administration (FDA) approved the menin inhibitor revumenib for the treatment of…

Read More

FDA approves belantamab mafodotin in combination with bortezomib and dexamethasone for R/R multiple myeloma

On October 23, 2025, the U.S. Food and Drug Administration (FDA) approved belantamab mafodotin, a BCMA-directed antibody and microtubule inhibitor…

Read More

A deep dive into PNH biology, diagnosis, and treatment

VJHemOnc is thrilled to bring you a feature article delving into the field of paroxysmal nocturnal hemoglobinuria (PNH).

Read More

FDA approves rilzabrutinib, a covalent BTK inhibitor, for patients with persistent or chronic immune thrombocytopenia

On August 29, 2025, the U.S. Food and Drug Administration (FDA) approved rilzabrutinib, an oral Bruton’s tyrosine kinase inhibitor (BTKi),…

Read More

Richter’s transformation: updated ERIC recommendations and emerging therapies in clinical trials

VJHemOnc is pleased to share a feature article that explores the latest updates in Richter’s transformation.

Read More

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals